Laboratory Of America Holdings: Tolmar Inc. Expands Research with New Facility at Rosalind Franklin University
- Tolmar Inc. establishes a new research facility at Rosalind Franklin University to enhance innovative drug development capabilities.
- The facility promotes collaboration with local scientists, driving advancements in specialized injectable treatments and pharmaceutical research.
- This expansion strengthens Tolmar's operational footprint in Illinois, aligning with its mission to improve patient care through specialized therapeutics.
Tolmar Inc. Expands Research Capabilities with New Facility at Rosalind Franklin University
Tolmar, Inc., a specialty pharmaceutical company recognized for its advanced long-acting injectable drug delivery solutions, establishes a new research facility at Rosalind Franklin University's Innovation and Research Park (IRP) in Illinois. Founded in 2007, Tolmar specializes in developing and manufacturing specialized injectables in urology, oncology, and endocrinology. The new laboratory enhances Tolmar’s ability to innovate and commercialize pharmaceutical products, complementing its existing operations based in Colorado. The expansion marks a significant milestone for the company, as it aims to bolster its regional presence and foster advancements in drug development.
The newly launched facility is a strategic addition to Tolmar's operations, featuring state-of-the-art research capabilities within the 100,000 square foot IRP, which houses six research centers focusing on critical areas, including cancer cell biology and immunology. Dr. Dave Loffredo, Tolmar’s vice president of innovation, articulates enthusiasm for the potential collaborations within the IRP’s vibrant research environment. He notes that the proximity to leading scientists and researchers offers unique opportunities for synergy, ultimately advancing the speed and effectiveness of product development. This collaborative atmosphere is expected to drive innovation, allowing Tolmar to navigate the complexities of pharmaceutical research with greater agility.
Dr. Stace Porter, senior vice president of development operations, emphasizes the advantages of establishing the new laboratory in Lake County, an emerging hub for life sciences. By tapping into the local network of academic and industry experts, Tolmar can reinforce its commitment to delivering specialized injectable treatments. The IRP’s focus on fostering partnerships will not only enhance Tolmar’s research capabilities but also promote a culture of innovation that is vital in the highly competitive pharmaceutical landscape. Dr. Joseph DiMario, RFU Executive Vice President for Research, echoes these sentiments, welcoming Tolmar and highlighting the potential for transformative collaborations that can lead to groundbreaking advancements in the sector.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

